ArticleEuropean journal of nuclear medicine and molecular imaging2026
A novel imaging approach in hyperparathyroidism: [68Ga]Ga-Trivehexin PET/CT.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the diagnostic performance of [68Ga]Ga-Trivehexin PET/CT for localizing hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism (PHPT) and to compare it with [99mTc]Tc-MIBI scintigraphy with SPECT/CT (MIBI scan).
methodsIn this retrospective study, patients with biochemically confirmed PHPT underwent both MIBI scan and [68Ga]Ga-Trivehexin PET/CT. Patient- and lesion-based detection rates were compared between modalities. [68Ga]Ga-Trivehexin PET/CT was acquired at approximately 40 ± 20 min after injection; delayed imaging at 80 ± 20 min was performed in a subset. Dynamic PET imaging was performed in three patients. Quantitative parameters, including SUVmax and lesion-to-background ratios, were recorded. Clinically relevant subgroups, including MEN-1-associated PHPT and persistent disease after surgery, were assessed.
resultsA total of 50 parathyroid-related lesions were evaluated in 38 patients. On patient-based analysis, MIBI scan and [68Ga]Ga-Trivehexin PET/CT correctly localized hyperfunctioning parathyroid tissue in 28 of 38 (74%) and 35 of 38 (92%) patients, respectively. On lesion-based analysis, [68Ga]Ga-Trivehexin PET/CT detected 49 of 50 lesions (98%), compared with 29 of 50 lesions (58%) detected by MIBI scan (P < 0.05). [68Ga]Ga-Trivehexin PET/CT demonstrated distinct focal uptake in 18 lesions with negative or equivocal MIBI findings. Dual-time-point imaging showed no significant differences in lesion SUVmax or lesion-to-background ratios between early and delayed scans. Dynamic imaging demonstrated a rapid increase in lesion contrast followed by a plateau, with no consistent improvement beyond approximately 25 min.
conclusion[68Ga]Ga-Trivehexin PET/CT demonstrated higher detection rates than MIBI scan for localizing hyperfunctioning parathyroid tissue in PHPT, particularly in multiglandular and subcentimetric disease. Early acquisition appears sufficient, with limited added value of delayed imaging.
Indexed as
Identifiers
42234003What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.